• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of meetings with sponsors that include discussion of Quality by Design (QbD) information. Cumulative total reported for the Fiscal Year.

Annual Target: 20%

Dictionary: Quality by Design (QbD): A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management (ICH Q8R2). The implementation of QbD will enhance the assurance of pharmaceutical quality in the U.S. market, improve the quality of Chemistry, manufacturing, and controls information submitted in Investigational New Drug (IND), New Drug Application (NDA), NDA supplement, and Drug Master File (DMF) submissions, and improve the ONDQA regulatory review processes.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2011

Skip graphic and jump to text data

Annual Target: 20%

TimeTargetPercent
Oct 2010N/A50
Nov 2010N/A50
Dec 2010N/A38
Jan 2011N/A27
Feb 2011N/A33
Mar 2011N/A29
Apr 2011N/A24
May 2011N/A17
Jun 2011N/A20
Jul 2011N/A20
Aug 2011N/A20
Sep 2011N/A19

Number of meetings with sponsors that included discussion of QbD information. Cumulative total reported for the Fiscal Year. (1)

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A1
Nov 2010N/A2
Dec 2010N/A3
Jan 2011N/A3
Feb 2011N/A6
Mar 2011N/A7
Apr 2011N/A7
May 2011N/A7
Jun 2011N/A6
Jul 2011N/A9
Aug 2011N/A9
Sep 2011N/A9

Footnotes

  • (1) Includes cancelled meetings where preliminary responses were sent

Number of meetings with sponsors. Cumulative total reported for the Fiscal Year. (1)

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A2
Nov 2010N/A4
Dec 2010N/A8
Jan 2011N/A11
Feb 2011N/A18
Mar 2011N/A24
Apr 2011N/A29
May 2011N/A42
Jun 2011N/A45
Jul 2011N/A45
Aug 2011N/A46
Sep 2011N/A48

Footnotes

  • (1) Includes cancelled meetings where preliminary responses were sent.

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.